Literature DB >> 12560282

Low dose methotrexate and bone marrow suppression.

Michael Sosin1, Sunil Handa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12560282      PMCID： PMC1125123          DOI： 10.1136/bmj.326.7383.266

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  9 in total

1.  Errors in prescribing methotrexate.

Authors:  B M Lomaestro; T S Lesar; T P Hager
Journal:  JAMA       Date:  1992-10-21       Impact factor: 56.272

2.  Haemopoietic toxicity and low-dose methotrexate.

Authors:  G A McArthur; M F Cole-Sinclair; M B Van Der Weyden
Journal:  Med J Aust       Date:  1992-02-17       Impact factor: 7.738

3.  Fatal outcome of low-dose methotrexate therapy in rheumatoid arthritis.

Authors:  R Omdal; L Gøransson; H Bergrem
Journal:  Clin Rheumatol       Date:  1993-06       Impact factor: 2.980

4.  Low dose methotrexate therapy--toxic if not taken correctly. Adverse Drug Reactions Advisory Committee.

Authors: 
Journal:  Med J Aust       Date:  1994-07-18       Impact factor: 7.738

5.  Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice.

Authors:  M L Grove; A B Hassell; E M Hay; M F Shadforth
Journal:  QJM       Date:  2001-06

6.  Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study.

Authors:  Hyon K Choi; Miguel A Hernán; John D Seeger; James M Robins; Frederick Wolfe
Journal:  Lancet       Date:  2002-04-06       Impact factor: 79.321

7.  Safety of low dose methotrexate in elderly patients with rheumatoid arthritis.

Authors:  B Hirshberg; M Muszkat; O Schlesinger; A Rubinow
Journal:  Postgrad Med J       Date:  2000-12       Impact factor: 2.401

8.  Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term?

Authors:  S M Griffith; J Fisher; S Clarke; B Montgomery; P W Jones; J Saklatvala; P T Dawes; M F Shadforth; T E Hothersall; A B Hassell; E M Hay
Journal:  Rheumatology (Oxford)       Date:  2000-10       Impact factor: 7.580

Review 9.  Methotrexate use in rheumatoid arthritis.

Authors:  J R O'Dell
Journal:  Rheum Dis Clin North Am       Date:  1997-11       Impact factor: 2.670
  9 in total
  15 in total

1.  Low-dose methotrexate-induced pancytopenia.

Authors:  Yogesh Preet Singh; Amita Aggarwal; Ramnath Misra; Vikas Agarwal
Journal:  Clin Rheumatol       Date:  2006-04-25       Impact factor: 2.980

2.  Methotrexate and bone marrow suppression: drug errors may be implicated in death.

Authors:  Matthew L Grove
Journal:  BMJ       Date:  2003-05-24

3.  Methotrexate and bone marrow suppression: standard collaborative care will be made more difficult.

Authors:  A K Clarke
Journal:  BMJ       Date:  2003-05-24

Review 4.  Oral pathology in inflammatory bowel disease.

Authors:  Miranda Muhvić-Urek; Marija Tomac-Stojmenović; Brankica Mijandrušić-Sinčić
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

Review 5.  Best practice in primary care pathology: review 10.

Authors:  W S A Smellie; N Shaw; R Bowley; M F Stewart; A M Kelly; P J Twomey; P R Chadwick; J B Houghton; J P Ng; A J McCulloch
Journal:  J Clin Pathol       Date:  2007-05-11       Impact factor: 3.411

Review 6.  Neutropenia in the Elderly: A Rheumatology Perspective.

Authors:  Su-Ann Yeoh; Christine Fox; Richard Hull
Journal:  Drugs Aging       Date:  2016-08       Impact factor: 3.923

7.  Severe bone marrow suppression due to methotrexate toxicity following aceclofenac-induced acute kidney injury.

Authors:  Robin George Manappallil; Durga Prasan; Jayameena Peringat; Illolil Kuniyil Biju
Journal:  BMJ Case Rep       Date:  2018-06-05

8.  Low-dose methotrexate in rheumatoid arthritis: a potential risk factor for bisphosphonate-induced osteonecrosis of the jaw.

Authors:  Paul C Mathai; Neelam N Andrade; Neha Aggarwal; Shibani Nerurkar; Prathmesh Kapoor
Journal:  Oral Maxillofac Surg       Date:  2018-03-05

9.  Safety of the concomitant use of methotrexate and a prophylactic dose of trimethoprim-sulfamethoxazole.

Authors:  Oh Chan Kwon; Jung Sun Lee; Yong-Gil Kim; Chang-Keun Lee; Bin Yoo; Seokchan Hong
Journal:  Clin Rheumatol       Date:  2018-01-30       Impact factor: 2.980

Review 10.  Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism.

Authors:  Fatima Iqbal; Wendy S Baker; Madiha I Khan; Shwetha Thukuntla; Kevin H McKinney; Nicola Abate; Demidmaa Tuvdendorj
Journal:  Br J Pharmacol       Date:  2017-03-23       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.